Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

OBX-115

PreclinicalSmall molecule

OObsidian Therapeutics, Inc.

OBX-115 is one of 12 small molecule programs targeting Tumor. It is currently in Preclinical.

1

Indications

2

Total Trials

2

Active Trials

11

Competitors

Pipeline

Status by Indication[3][1]

Indication

TumorRecruiting

TumorPreclinical

Recruiting

Competition

Competitive Landscape

13 competitors in Tumor

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Opdivo

Bristol-Myers Squibb

Tuoyi

CCoherus Oncology, Inc.

Giapreza

LLa Jolla Pharmaceutical Company

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

LM-302

LLaNova Medicines Zhejiang Co., Ltd.

MRI Contrast-Enhancing Agents

HP518 - Dose Expansion

HHinova Pharmaceuticals Aus Pty Ltd

ASK120067

JJiangsu Aosaikang Pharmaceutical Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Metastatic Melanoma

NCT05470283

Q2 2029

PreclinicalRecruiting

Tumor

NCT06060613

Clinical

Trials by Indication[1]

Metastatic Melanoma1 trial

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05470283·21 enrolled

Tumor1 trial

A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors

Recruiting·OObsidian Therapeutics, Inc.·Preclinical·NCT06060613·208 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for OBX-115. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OBX-115 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OBX-115. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Obsidian Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OObsidian Therapeutics, Inc.

Related News